logo
Share SHARE
FONT-SIZE Plus   Neg

Catalyst Pharmaceutical Partners Raises $6 Mln In Registered Direct Offering

Catalyst Pharmaceutical Partners Inc. (CPRX) has reached definitive agreements to sell 4.0 million common shares, and common stock purchase warrants to buy an aggregate of 1.2 million shares, in a registered direct public offering. The aggregate offering price for each share and corresponding warrant is $1.50, resulting in gross proceeds of $6 million.

The common stock purchase warrants have a five year-term and an exercise price of $2.08 per share. The offering may close on or about August 31, 2012. Catalyst expects to use the net proceeds from this offering to fund costs associated with the company's product development efforts and for general corporate purposes. Roth Capital Partners has acted as the exclusive placement agent for the transaction.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
U.S. Bancorp (USB) reported net income of $1.56 billion for the third quarter of 2017, or $0.88 per share, compared to $1.50 billion, or $0.84 per share, in the third quarter of 2016. On average, 28 analysts polled by Thomson Reuters expected the company to report profit per share of $0.88 for the quarter.... Dutch semiconductor equipment maker ASML Holding NV reported Wednesday higher profit in its third quarter as sales were boosted mainly with strong demand for DUV Systems. Meanwhile, margin declined. Looking ahead, the company projects sequentially lower sales in its fourth quarter. For fiscal 2017, the company maintained forecast for higher sales. Leaders of the Senate Health Committee revealed Tuesday they have reached an agreement on legislation to provide short-term stability to Obamacare. Committee Chairman Lamar Alexander, R-Tenn., and ranking member Patty Murray, D-Wash., announced the bipartisan agreement.
comments powered by Disqus
Follow RTT